NeurologyLive® Friday 5 — October 3, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Guardrails for Blood-Based Biomarker Testing in Specialty Care: Rebecca Edelmayer, PhD

The vice president of scientific engagement at the Alzheimer’s Association provided clinical insights on the most major considerations and precautions clinicians should have about diagnostic and commercially available tests for suspected Alzheimer disease. [WATCH TIME: 3 minutes]

2: Using MRI-Machine Learning to Identify Disease Subtypes in Multiple Sclerosis: Alessia Bianchi, MD

At ECTRIMS 2025, the postdoctoral research fellow at the University of Siena in Italy talked about how machine learning could classify multiple sclerosis into biologically distinct subtypes. [WATCH TIME: 5 minutes]

3: Applying the 2024 Diagnostic Criteria for MS to Enable Earlier Intervention: Erin Longbrake, MD, PhD

At ECTRIMS 2025, the associate professor of neurology at Yale School of Medicine talked about the 2024 diagnostic criteria, the preclinical phase of the disease, and progressive MS. [WATCH TIME: 3 minutes]

4: NeuroVoices: Carol Abraham, on Awareness, Advocacy, and Life With LGMD

In our latest NeuroVoices Q&A, the president of the LGMD Foundation discussed raising awareness, strengthening advocacy, and the lived experience of navigating limb-girdle muscular dystrophy.

5: Highlighting Research Progress and Upcoming NMOSD Clinical Trial: Sumaira Ahmed

The executive director of The Sumaira Foundation (TSF) talked about TSF's research update and award ceremony held during ECTRIMS 2025. [WATCH TIME: 5 minutes]